# Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

> **NCT01504711** · NA · COMPLETED · sponsor: **Philip Philip** · enrollment: 30 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Nausea Post Chemotherapy

## Interventions

- **DRUG:** fosaprepitant dimeglumine

## Key facts

- **NCT ID:** NCT01504711
- **Lead sponsor:** Philip Philip
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2016-12-29
- **Final completion:** 2020-09-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01504711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01504711, "Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01504711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*